- Home
- WLYB vs MRUS Comparison
WLYB vs MRUS Comparison
Compare WLYB & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- MRUS
- Stock Information
- Founded
- WLYB 1807
- MRUS 2003
- Country
- WLYB United States
- MRUS Netherlands
- Employees
- WLYB N/A
- MRUS N/A
- Industry
- WLYB Books
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- MRUS Health Care
- Exchange
- WLYB Nasdaq
- MRUS Nasdaq
- Market Cap
- WLYB 2.3B
- MRUS 2.7B
- IPO Year
- WLYB N/A
- MRUS 2016
- Fundamental
- Price
- WLYB $44.00
- MRUS $40.90
- Analyst Decision
- WLYB
- MRUS Strong Buy
- Analyst Count
- WLYB 0
- MRUS 14
- Target Price
- WLYB N/A
- MRUS $87.00
- AVG Volume (30 Days)
- WLYB 199.0
- MRUS 770.0K
- Earning Date
- WLYB 06-12-2025
- MRUS 05-07-2025
- Dividend Yield
- WLYB 3.21%
- MRUS N/A
- EPS Growth
- WLYB N/A
- MRUS N/A
- EPS
- WLYB 0.75
- MRUS N/A
- Revenue
- WLYB $1,703,491,000.00
- MRUS $54,732,000.00
- Revenue This Year
- WLYB N/A
- MRUS $26.81
- Revenue Next Year
- WLYB $1.13
- MRUS $23.85
- P/E Ratio
- WLYB $58.26
- MRUS N/A
- Revenue Growth
- WLYB N/A
- MRUS 42.77
- 52 Week Low
- WLYB $35.68
- MRUS $33.19
- 52 Week High
- WLYB $52.90
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- WLYB 65.28
- MRUS 45.06
- Support Level
- WLYB $39.54
- MRUS $37.92
- Resistance Level
- WLYB $44.15
- MRUS $46.36
- Average True Range (ATR)
- WLYB 0.01
- MRUS 2.58
- MACD
- WLYB 0.11
- MRUS -0.27
- Stochastic Oscillator
- WLYB 86.96
- MRUS 35.31
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.